Last reviewed · How we verify

OTULFI (USTEKINUMAB-AAUZ)

FRESENIUS KABI USA · FDA-approved approved Under review Quality 6/100

OTULFI (generic name: USTEKINUMAB-AAUZ) is a Interleukin-12 Antagonist [EPC] drug developed by FRESENIUS KABI USA. It is currently FDA-approved.

OTULFI (also known as STELARA) is an interleukin-12 inhibitor, classified as an antibody. It works by inhibiting interleukin-12, a specific molecular target.

At a glance

Generic nameUSTEKINUMAB-AAUZ
SponsorFRESENIUS KABI USA
Drug classInterleukin-12 Antagonist [EPC]
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about OTULFI

What is OTULFI?

OTULFI (USTEKINUMAB-AAUZ) is a Interleukin-12 Antagonist [EPC] drug developed by FRESENIUS KABI USA.

Who makes OTULFI?

OTULFI is developed and marketed by FRESENIUS KABI USA (see full FRESENIUS KABI USA pipeline at /company/fresenius-kabi-usa).

What is the generic name of OTULFI?

USTEKINUMAB-AAUZ is the generic (nonproprietary) name of OTULFI.

What drug class is OTULFI in?

OTULFI belongs to the Interleukin-12 Antagonist [EPC] class. See all Interleukin-12 Antagonist [EPC] drugs at /class/interleukin-12-antagonist-epc.

What development phase is OTULFI in?

OTULFI is FDA-approved (marketed).

What are the side effects of OTULFI?

Common side effects of OTULFI include Nasopharyngitis, Upper respiratory tract infection, Headache, Fatigue, Back pain, Dizziness. Serious adverse events: Serious infections, Malignancies (excluding non-melanoma skin cancer), Non-melanoma skin cancer, Posterior reversible encephalopathy syndrome (PRES).

Related